AlphAIAlphAI — Financial news for AI agents
stocktitan.net$STLN

Investors can hear Starling Oncology discuss Q3 results at 5 p.m. ET Nov. 5.

Starling Oncology (STLN) will release Q3 2026 financial results on Nov. 5, followed by a conference call at 5 p.m. ET. The call can be accessed live or via replay, and a webcast is available on the company's website. STLN is a community oncology care provider with over 100 clinics across five states.

Original reporting
stocktitan.net
Published Oct 26, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 1:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$STLN
Neutral
medium confidence
Mentioned
$STLN
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$STLNNeutralLow
01

Why it matters

The scheduled earnings call provides a clear date for investors to plan trades; no immediate catalyst beyond the announcement.

02

Market read

A routine earnings‑release announcement; modest relevance for short‑term traders.

03

What to watch

Potential hidden guidance or market expectations embedded in the timing of the call.

Relevance 5/10Novelty 4/10Timing: Nov 5 2026 earnings release

Background

Starling Oncology is a Nasdaq‑listed community oncology provider that regularly announces quarterly earnings.

Company-level read

Ticker impact

$STLNNeutralMedium confidence
Context

Starling Oncology announced its Q3 2026 results will be released on Nov 5, 2026 with a conference call at 5 p.m. ET.

Expected impact

neutral as market awaits the actual results; limited immediate pressure

Evidence & confidence

No financial numbers are disclosed; traders may hold or lightly position pending the earnings release.

Market effects

Sector

Sets a timeline for the community oncology sector; peers may see similar upcoming disclosures.

Regional

Limited to U.S. small‑cap biotech investors.

Global

Minimal; primarily relevant to investors tracking Starling Oncology.

Counterpoint

What could challenge this read

Without new guidance, the announcement may be ignored; price could stay flat.

Key entities

  • company
    Starling Oncology, Inc.

    NASDAQ-listed oncology care provider (ticker STLN).

Read at source← All news

Related articles

$STLNMedAI 8/10

Oncology Institute Q3 Earnings Call Highlights

Oncology Institute (STLN) reported Q3 gross profit of $30.7M, up from $18.9M, with gross margin increasing to 18.1%. Capitated revenue rose 39.5% to $28.7M, while fee-for-service revenue fell 21% to $31.3M. The company expects 100% capitated revenue growth in 2027 and updated its 2026 outlook, including revenue of $650M-$660M and gross profit of $107M-$110M. STLN ended Q3 with $36.9M in cash.

finance.yahoo.com
$STLNMed

Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Starling Oncology, Inc. (STLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance CERRITOS, Calif., November 5, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community o

SEC EDGAR 8-K
$CGONHigh

Why is CG Oncology stock surging today?

CG Oncology (CGON) stock rose 19.7% after Q3 2026 results showed a smaller-than-expected loss of $0.64 per share and revenue of $1.60M, both beating estimates. The company announced upcoming clinical trial data and a BLA submission, with a cash position of $984.5M. Analysts have a 'Moderate Buy' rating and $87.50 average price target.

investing.com
$GMEDHighAI 8/10

Why is Globus Medical stock plunging today?

Globus Medical (GMED) stock fell 12.5% to $71.26, a 52-week low, after Q3 2026 revenue missed estimates at $763.7M, down 0.7% YoY. The company cut full-year revenue guidance to $3.09B. Analysts downgraded the stock, citing weak growth outlook and insider selling. The S&P 500 and Nasdaq rose, but GMED underperformed.

investing.com